



HAL
open science

Can Some Anticancer Treatments Preserve the Ovarian Reserve?

Nicolas Vallet, Nicolas Boissel, Elisabeth Elefant, Florian Chevillon, H el ene Pasquer, Charlotte Calvo, Nathalie Dh edin, Catherine Poirot

► To cite this version:

Nicolas Vallet, Nicolas Boissel, Elisabeth Elefant, Florian Chevillon, H el ene Pasquer, et al.. Can Some Anticancer Treatments Preserve the Ovarian Reserve?. *Oncologist*, In press, 10.1002/onco.13675 . hal-03121063

HAL Id: hal-03121063

<https://hal.sorbonne-universite.fr/hal-03121063>

Submitted on 26 Jan 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destin ee au d ep ot et  a la diffusion de documents scientifiques de niveau recherche, publi es ou non,  emanant des  tablissements d'enseignement et de recherche fran ais ou  trangers, des laboratoires publics ou priv es.

1 **Article type:** narrative review

2

3 **CAN SOME ANTICANCER TREATMENTS PRESERVE THE OVARIAN RESERVE?**

4

5 **Short title:** Targeted therapies and fertility preservation

6

7 Nicolas Vallet,¹ Nicolas Boissel,^{2,3} Elisabeth Elefant,^{4,5} Florian Chevillon,² H el ene Pasquer,² Charlotte

8 Calvo,⁶ Nathalie Dhedin,² Catherine Poirot^{2,5}

9

10 1. Department of Hematology and Cellular Therapy, Tours University Hospital, Tours, France

11 2. Department of Hematology, Adolescent and Young Adults Unit, Fertility Preservation, Saint Louis Hospital,
12 APHP, Paris, France

13 3. Paris University, EA-3518, Paris, France

14 4. Centre de R ef erence sur les Agents T eratog enes (CRAT), Armand Trousseau Hospital, AP-HP, Paris, France.

15 5. Faculty of Medicine, Sorbonne University, Paris, France.

16 6. Pediatric Hematology Department, Robert Debr e Hospital, AP-HP, Paris, France.

17

18 **Corresponding author:**

19 Dr. Nicolas Vallet, Department of Hematology and Cellular Therapy, Tours University Hospital, 2

20 boulevard Tonnell e, 37000 Tours, France. Tel + 33 2 4242 3712, Fax + 33 2 4747 3811.

21 nicolas.vallet@inserm.fr

22

23 **Word count:** abstract: 250; implication for practice: 96; main text: 4797

24 **Number of Figures:** 4, **number of Table:** 1

25 **Supplemental Material:** no appendices

26

27

28

29

30 **KEYWORDS**

31 premature ovarian failure, chemotherapy, targeted therapy, cancer, fertility preservation

1 **ABSTRACT**

2

3 **Background:** Preventing premature ovarian failure (POF) is a major challenge in oncology. With
4 conventional regimens, cytotoxicity-associated POF involves primordial follicles (PF) pool depletion by
5 apoptosis or overactivation mechanisms, notably mediated by the ABL/TAp63 and PI3K/Akt/mTOR
6 pathways. New anticancer treatments have been designed to target pathways implicated in tumor
7 growth. Although, concerns regarding fertility arise with these targeted therapies, we hypothesized that
8 targeted therapies may exert off-tumor effects on PF that might delay POF. We provide an overview of
9 evidences concerning these off-tumor effects on PF. Limitations and future potential implications of
10 these findings are discussed.

11 **Design:** PubMed was searched by combining Boolean operators with the keywords: fertility, ovarian,
12 follicle, anti-tumoral, cancer, targeted, cytotoxic, chemotherapy.

13 **Results:** Cisplatin-related PF apoptosis via the ABL/TAp63 pathway was targeted with a tyrosine
14 kinase inhibitor, imatinib, in mice, but effects were recently challenged by findings on human ovarian
15 xenografts in mice. In cyclophosphamide-treated mice, PI3K/Akt/mTOR pathway inhibition with mTOR
16 inhibitors and AS101 preserved the PF pool. Proteasome and GSK3 inhibitors were evaluated for
17 direct and indirect follicle DNA damage prevention. Surprisingly, evidence for cytotoxic drug
18 association with PF pool preservation were found. We also describe selected non-anticancer
19 molecules which may minimize gonadotoxicity.

20 **Conclusions:** Not all anticancer treatments are associated with POF, particularly since the advent of
21 targeted therapies. The feasibility of associating a protective drug targeting PF exhaustion
22 mechanisms with cytotoxic treatments should be evaluated, as a way of decreasing the need for
23 conventional fertility preservation techniques. Further evaluations are required for transfer into clinical
24 practice.

25

26

27

28

29

30

1 **IMPLICATIONS FOR PRACTICE**

2

3 Anticancer therapies are associated with infertility in 10% to 70% patients which is the result of
4 primordial follicles pool depletion. Alone or associated with gonadotoxic treatments, some targeted
5 therapies may exert favorable off-targets effects on primordial follicle pool by slowing down their
6 exhaustion. Current evidences of these effects rely on murine models or human in vitro models.

7 Evaluations of these protective strategies in humans is challenging but if these results are confirmed
8 with clinical and biological data not only it could be a new approach to female fertility preservation, but
9 it will change standard fertility strategies.

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

1 INTRODUCTION

2

3 Fertility preservation during cancer treatment is challenging [1]. In female patients, premature ovarian
4 failure (POF) is associated not only with infertility, but also with hormonal disorders, leading to
5 osteoporosis and cardiovascular diseases, which can impair both quality of life (QOL) and survival [2].
6 Cytotoxic treatments are associated with POF in 10% to 70% patients, depending on the alkylating
7 agents or ovarian irradiation doses used and the age of the patient at treatment [3].

8 Fertility preservation based on the freezing of embryos, oocytes or ovarian tissue requires
9 ovarian stimulation and/or surgical approaches that may not be appropriate for use in emergency
10 conditions or in patients with hormone-sensitive cancers [1,4]. Autologous grafts of cryopreserved
11 ovarian cortex tissue can restore fertility and ovarian endocrine functions, but concerns have been
12 raised about tissue contamination with minimal residual disease, which may contraindicate
13 transplantation [1,5,6].

14 The primordial follicle (PF) pool, also known as the ovarian reserve, is fixed and determined at
15 time of birth. Menopause, or POF in young patients is related to the depletion of this reserve. It occurs
16 with successive PF activation, a process in which individual primordial follicles leave their dormant
17 state and enter a growth phase. PF activation is mediated, in particular, by the phosphatidylinositol 3-
18 kinase(PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway, following KIT activation [7,8].
19 Cytotoxic agents, such as platinum salts, have been shown to promote apoptosis via the ABL/TAp63
20 pathway [9].

21 Over the last 20 years, a growing number of anticancer treatments have been designed to
22 target proteins involved in tumor growth or survival pathways, including some involved in PF
23 activation, such as the ABL protein kinase, mTOR complex 1 (mTORC1) or mTORC2 (Figure 1). We
24 hypothesized that these anticancer drugs might have on-target/off-tumor effects on PF activation or
25 death pathways that might preserve the ovarian reserve. In this review, we provide an overview of
26 current evidence concerning the mechanisms by which targeted or conventional anticancer treatments
27 may target PF activation or apoptosis pathways, thereby contributing to protection of the ovarian
28 reserve.

29 In April 2019, we searched the PubMed database for studies reporting a specific association
30 of anticancer treatments with signs of ovarian reserve protection. We used the following keywords,

1 together with Boolean operators: fertility, ovarian, follicle, anti-tumoral, cancer, targeted, cytotoxic,
2 chemotherapy. The initial search of PubMed was then complemented with targeted queries. No
3 limitations relating to study methodology were applied, and ovarian reserve protection was defined as
4 increases in primordial follicles count, pregnancy rate and time-to-POF.

5

6 **CELLULAR PATHWAYS INVOLVED IN PRIMORDIAL FOLLICLE ACTIVATION**

7

8 The constitution of the PF pool and the number of follicles it contains are determined during
9 intrauterine development. This pool, also known as the ovarian reserve, and the rate of PF loss,
10 determine the duration of ovarian activity. The mean number of PFs at birth ranges from one to two
11 million then decreases with age, ultimately resulting in the menopause (Figure 2) [10]. The rate of
12 decrease in the ovarian reserve depends on activating and maintenance signals. The pathways
13 involved in PF activation have already been reviewed in detail and are summarized below, highlighting
14 targetable pathways (Figure 3) [7,8].

15 PI3K signaling is the cornerstone of differentiation and proliferation signaling. The PI3K
16 pathway is triggered by the activation of the KIT receptor by its ligand (KIT-L), which is secreted by
17 granulosa cells and oocytes. PI3K activates Akt, in turn leading to the activation of mTORC1 and
18 mTORC2. Downstream, this pathway leads to the activation of 4E-BP1 and ribosomal protein S6
19 (RPS6), which are involved in cell survival and growth [7]. Conversely, PI3K/Akt/mTORC signaling is
20 downregulated by phosphatase and tensin homolog (PTEN). In *Pten-null* mice, the PI3K pathway is
21 constitutively activated, leading to PF exhaustion [7,11]. KIT-L expression is controlled by oocytes and
22 granulosa cells, which secrete molecules, such as platelet-derived growth factor (PDGF), basic
23 fibroblast growth factor and leukemia inhibitory factor, that have been shown to promote the primordial
24 to primary follicle transition [12]. The JAK/STAT pathway is also involved in the inhibition of PF growth,
25 notably through JAK1 activation [13], and stromal cells can activate follicles by secreting bone
26 morphogenetic protein-4 (BMP-4) and keratinocyte growth factor (KGF) [7]. In addition, ovarian cell-to-
27 cell contact promotes the inactivation of Hippo signaling, which has been shown to promote follicle
28 activation through PI3K/Akt/mTOR signaling [14].

29

30

1 **MECHANISMS INVOLVED IN PREMATURE OVARIAN FAILURE AFTER CYTOTOXIC**
2 **TREATMENT**

3

4 The pathogenesis of ovarian damage after chemotherapy has been reviewed in detail elsewhere [15].
5 The mechanisms underlying PF exhaustion involve apoptosis or PF overactivation, and depend on the
6 cytotoxic agents used [15]. The ABL/TAp63 and PI3K/Akt/mTOR pathways are the principal pathways
7 implicated in POF. Ovarian stroma damage may also lead to POF, but the interaction between follicles
8 and the ovarian stroma remains poorly understood (Figure 4A).

9

10 Signaling pathways involved in cytotoxicity-related effects on follicles

11 In humans, comparisons of patients on chemotherapy regimens including alkylating agents with age-
12 matched healthy controls demonstrated a decrease in the PF pool in the treated patients [16]. TUNEL
13 analyses of human ovaries after CY administration in a xenografted mouse model have also revealed
14 follicle apoptosis [17]. TUNEL analyses of the ovaries in CY-treated mice did not reveal signs of
15 apoptosis for the ovarian cortex, suggesting that PF loss might not result from direct injury through
16 apoptosis [18]. Independent research teams have shown that the PF loss in CY-treated mice is
17 associated with an increase in growth rate. This overactivation is responsible for PF exhaustion.
18 Higher levels of p-Akt, p-mTOR and p-RPS6 expression have been demonstrated in the ovaries of
19 CY-treated mice [18-20].

20 Ovaries from xenografted SCID mice treated with DOX display an increase in apoptosis,
21 particularly in cortical cells potentially corresponding to PF [21]. In *ex vivo* cultures of mouse ovaries,
22 DOX has been shown to be associated with granulosa cell apoptosis [22]. This apoptosis results from
23 double-strand breaks caused by the ATM/ABL/TAp63 pathway in mice xenografted with human
24 ovarian tissue [21]. Oxidative damage may also be involved in the ovarian damage caused by DOX
25 [23].

26 In a mouse model, CIS has been shown to activate cell death mechanisms via the TAp63
27 protein (a P53 homolog). The TAp63 protein may be activated by a pathway involving ABL, although
28 this remains a matter of debate [9,24-26]. Following CIS administration, TAp63 promotes ABL
29 expression, leading to TAp73-BAX-mediated apoptosis [26]. Studies of *ex vivo* cultures of mouse

1 ovaries have suggested that CIS may preferentially damage oocytes rather than granulosa cells,
2 through apoptosis mechanisms [22].

3

4 Effects mediated by alterations to the ovarian stroma

5 Follicle growth homeostasis requires functional stromal cells and vascularization. Fabbri *et al.* showed
6 that DOX and CIS induce apoptosis in ovarian stromal cells through BAX expression and Bcl
7 overexpression, in studies of cultured adherent *ex vivo* cells from cryopreserved human ovarian
8 tissues [27]. DOX also affects microvessel formation and blood flow through these vessels [21,28].

9

10 **EVIDENCE THAT SOME ANTICANCER TREATMENTS CAN PROTECT THE OVARIAN RESERVE**

11

12 Tyrosine kinase inhibitors

13 *Imatinib*

14 Imatinib is a well-known tyrosine kinase inhibitor (TKI) specifically targeting the ABL kinase domain of
15 the BCR-ABL1 oncogenic protein in chronic myeloid leukemia [29]. However, it has been shown to
16 have off-target effects [30]. In particular, it inhibits the platelet-derived growth factor receptor (PDGFR)
17 and KIT tyrosine kinases, particularly in the contexts of gastrointestinal stromal and oligodendroglial
18 tumors [31-33]. PF apoptosis and activation are mediated by the ABL and KIT pathways, respectively,
19 suggesting that imatinib may prevent ovarian damage due to these pathways.

20 Imatinib alone was found to have no impact on the PF pool in five-week-old mice into which
21 BCR-ABL1 cells were injected. However, ovarian morphology was disorganized in these mice [34].
22 These findings were confirmed following the treatment of postnatal day 2 (PND2) rats with imatinib for
23 three days [35].

24 The effect of imatinib on oocyte damage after chemotherapy was investigated with an *in vitro*
25 model of cultured mouse ovaries. Ovaries were cultured with DOX or CIS, alone or together with
26 imatinib. In this study, imatinib was associated with a smaller number of morphologically classified
27 unhealthy follicles after CIS treatment, whereas the effect of DOX was not affected by the addition of
28 imatinib [22]. As ABL could potentially induce TAp63 after DNA damage in CIS-treated mice,
29 combined treatment with imatinib was evaluated *in vivo*. In cultured ovaries from PND5 mice,
30 combined treatment with imatinib was associated with lower levels of ABL and TAp63 expression and
31 lower rates of apoptosis [9]. The longer term impact of imatinib and CIS co-administration was

1 evaluated in three-week-old ovariectomized mice into which *in vitro*-treated mouse ovaries were
2 grafted [26]. PF numbers were larger in mice receiving grafts of ovarian tissue subjected to the
3 combined treatment than in mice receiving grafts of ovaries treated with CIS only, which displayed no
4 signs of ovarian tissue recovery [26]. Pooled primordial and primary follicle counts, mean number of
5 pups and pregnancy rates were also higher in mice receiving ovarian tissue subjected to the combined
6 treatment than in mice receiving ovarian tissue treated with CIS alone [9]. However, this findings were
7 challenged by Kerr *et al.*, who reported that the combined treatment was not associated with higher PF
8 counts or a larger number of pups in a comparable mice model [24]. Kerr *et al.* also reported an
9 association between imatinib treatment and a decrease in the number of PF [24]. They evaluated the
10 effects of imatinib injected with or before CIS, whereas Gonfloni *et al.* administered imatinib and CIS at
11 the same time [9]. Finally, the differences in the results obtained by these two team may reflect
12 differences in the type of CIS used. Kerr *et al.* used hospital-grade CIS and reported higher follicle
13 toxicity at the same dose than was reported for SIGMA-CIS in the work of Gonfloni *et al.* [9,24].
14 Together, these results highlight the importance of CIS dose in experimental models. ABL was thought
15 to be targeted in these experiments, but it remains possible that the effects of imatinib were due to KIT
16 inhibition. Thus, imatinib may prevent follicle activation by cytotoxic agents, as illustrated by the low
17 Ki67 levels observed in PF granulosa cells from imatinib-treated rats [35].

18 But, studies of human ovarian xenografts in mice and *ex vivo* cultures have reported different
19 effects of imatinib in human ovarian tissues [36]. The use of a combination of CIS (Eli Lilly and
20 Company) and imatinib to treat xenografted mice and *ex vivo* cultures of healthy human ovarian
21 tissues was associated with a PF count similar to that obtained following treatment with CIS alone.
22 Small follicles lacking oocytes and with a bizarre shape were observed in imatinib-treated ovaries [36].

23

24 *Sunitinib*

25 Sunitinib is a multikinase inhibitor targeting proteins involved in PF activation, such as PDGFR and
26 KIT, that is used in kidney cancers [37]. In three-week-old mice, sunitinib treatment was associated
27 with lower oocyte levels after superovulation tests. In unstimulated six-week-old mice, the PF pool of
28 sunitinib-treated mice was similar to that in controls. Litter size was also found to be similar for treated
29 mice and controls. In parallel, in cultured granulosa cell lines, p-ERK1/2 (a marker of proliferation)
30 expression was found to be lower in the granulosa cells and oocytes of treated mice [38]. Thus,

1 sunitinib may counteract PF activation after the administration of cytotoxic agents. This hypothesis has
2 not been tested in co-administration studies.

3

4 mTOR inhibitors

5 mTOR inhibitors are immunosuppressors used in the contexts of breast cancer treatment and solid
6 organ or hematopoietic stem cell transplantation [39-41]. The PI3K/Akt/mTOR pathway is
7 overactivated in CY-treated mice [18-20]. *Pten-null* mice were used to model PI3K/Akt/mTOR
8 overactivation as PTEN downregulates this pathway [7]. Rapamycin was the first mTOR inhibitor to be
9 tested in *Pten-null* mice; it was found to lead to a decrease in p-RPS6 and higher PF counts than in
10 untreated mice [42]. The administration of rapamycin in eight-week-old rats led to a doubling of the
11 proportion of PFs, whereas the proportions of antral, atretic and corpora lutea decreased [43].
12 Immunoblots revealed that mTOR and p-PS6K1 (the RPS6 activation enzyme) levels were lower in
13 the ovaries of treated rats than in those of untreated rats [43].

14 Combined treatment with rapamycin and CY decreases PF exhaustion through the
15 PI3K/Akt/mTOR pathway. In eight-week-old mice, CY treatment is not associated with an increase in
16 PF apoptosis. By contrast, the proliferation index was found to be higher for the PF of treated mice,
17 which had lower PF counts. In mice receiving the combined treatment, PF counts were higher, and
18 lower levels of mTOR and p-RPS6 expression were observed [18]. This effect is not specific to
19 rapamycin. The PF pool was also preserved following the co-administration of everolimus or
20 sapanisertib (INK128), this combined treatment being associated with lower levels of p-AKT and p-
21 PS6K1 detection in PFs. The inhibition of p-4EBP1 in PFs was observed only with sapanisertib
22 cotreatment. Interestingly, in the remaining fertile animals given CY alone, the number of pups per
23 litter was lower than that for mice receiving the combined treatment [19].

24 The effect of mTOR inhibitors has also been studied *ex vivo*, with cultures of thawed human
25 ovarian tissue from 19- to 29-year-old female patients (the indications for tissue preservation were not
26 described). Everolimus limited PF loss and decreased the number of growing follicles. The effect of
27 everolimus on p-RPS6 observed in mice was also demonstrated in human follicles [14]. This suggests
28 that the mouse model is of relevance to humans. mTOR inhibitors may, therefore, help to protect the
29 ovarian reserve, by blocking PF activation without impairing ovarian hormonal function.

30

1 AS101

2 AS101 is a low-molecular weight organic tellurium compound with immunomodulatory activities. It has
3 been shown to decrease p-Akt levels in cultured mouse multiple myeloma cell lines [49]. AS101 has
4 been evaluated in CY-treated mice, in which it was associated with a lower ratio of growing to non-
5 growing follicles. Co-treatment was also associated with lower levels of p-rpS6, whereas p-Akt levels
6 were similar to those observed after treatment with CY alone, suggesting that AS101 might act
7 downstream in the PI3K/Akt signaling pathway. Co-treatment preserved ovarian function, as
8 demonstrated by its effects on litter size and cumulative pup numbers, which were similar to those in
9 controls and greater than those for CY alone [20].

10

11 Proteasome inhibitor

12 Bortezomib is a proteasome inhibitor approved for use in the treatment of multiple myeloma [44].
13 Following the demonstration that the proteasome transports anthracycline to the nucleus, leading to
14 DNA damage, the potential of bortezomib to protect against the damaging effects of anthracycline was
15 studied in mice [45]. Mice received either bortezomib or a control followed by a DOX injection. Mice
16 treated with bortezomib and DOX had fewer DNA breaks per ovarian cell. Co-treatment with
17 bortezomib was also associated with a decrease in the rate of secondary follicle cell apoptosis and a
18 larger litter size than treatment with DOX alone [46]. The DOX-induced apoptosis of PFs was
19 prevented by bortezomib administration, but this study did not assess apoptosis in the follicles.

20

21 Glycogen synthase kinase 3 (GSK3) inhibitors

22 GSK3 is a serine/threonine protein kinase that interacts with Akt in the PI3K/Akt/mTOR pathway [47].
23 It is involved in reactive oxygen species (ROS) detoxification through mechanisms decreasing nuclear
24 factor erythroid 2-like 2 (Nrf2) translocation to the nucleus, favoring ROS-induced cell death [48].
25 GSK3 inhibitors are currently under evaluation in phase I and II studies for use in the treatment of
26 cancer (the NCT03678883 and NCT04239092 trials in particular). DOX induces cell damage through
27 ROS. The effects of GSK3 inhibitors on folliculogenesis after DOX administration were therefore
28 studied in mice. DOX administration with these inhibitors were associated with lower levels of ROS
29 markers (malondialdehyde) and higher levels of antioxidant protein synthesis and expression
30 (superoxide dismutase and glutathione peroxidase). Nrf2 expression and synthesis levels were also

1 higher in co-treated mice. In parallel, PF counts were higher in co-treated mice than in mice treated
2 with DOX alone [23].

3

4 Cytotoxic drugs

5 ABVD (adriamycin [doxorubicin], bleomycin, vinblastine, dacarbazine) is a polychemotherapy regimen
6 frequently used in the first-line treatment of Hodgkin lymphoma. McLaughlin *et al.* reported that ABVD-
7 treated patients ($n=8$) had a higher proportion of non-growing follicles than controls [50]. The controls
8 for this study included untreated patients ($n=3$), patients treated with OEPA-COPDAC (vincristine,
9 etoposide, doxorubicin, prednisone-cyclophosphamide, vincristine, prednisone, dacarbazine; $n=3$),
10 and women undergoing elective cesarean section ($n=12$). In parallel, mean follicle density (MFD)
11 increased in ABVD-treated patients to levels even higher than the expected MFD for age [50].

12 The cytotoxic agents included in ABVD chemotherapy were studied individually. Adriamycin is
13 a brand name for the anthracycline DOX. In a retrospective setting, DOX was found to be associated
14 with an increase in the risk ratio of pregnancy [1.22 (95%CI: 1.04-1.45)]. This case-controlled study
15 included female cancer survivors, treated before the age of 21 years, without fertility preservation.
16 Exposure to cytotoxic drugs was assessed on the basis of medical records [51]. This surprising
17 observation may reflect an uncontrolled bias or alpha risk inflation, given that DOX has been reported
18 to be associated with PF loss in mice [21,22]. The ABVD regimen also contains vinblastine, an alkaloid
19 agent like vincristine. The impact of vincristine on the ovarian reserve was evaluated in eight-week-old
20 and six-month-old mice. PF counts were unaffected by vincristine administration, whereas pre-antral
21 and antral follicle counts decreased. Remarkably, atretic follicle counts were higher in treated mice
22 than in controls [52], suggesting an impact of vincristine on growing follicles but not on PFs.
23 Nevertheless, these results are not consistent with a hypothetical protective effect of ABVD on the
24 ovarian reserve.

25

26 **OTHER MOLECULES MAY MINIMIZE CHEMOTHERAPY-RELATED GONADOTOXICITY**

27 Non-anticancer molecules were also reported to minimize chemotherapy-related gonadotoxicity
28 possibly by targeting apoptosis or PF activation pathways.

29

30

1 Sphingolipids

2 Sphingosine-1-phosphate (S1P) and ceramide-1-phosphate (C1P) are two sphingolipid compounds
3 that were shown to impact cell survival [53,54]. In mice xenotransplanted with human ovarian cortical
4 pieces co-administration of S1P with DOX and CY was associated with lower rate of apoptosis
5 measured in PF by immunohistochemistry assays for activated capsase-3 [55]. This result was also
6 reported with busulfan by an independent team which also reported higher PF count with co-
7 administration procedure [56]. C1P associated with CY was associated with higher PF count. The
8 effect may be also related to inhibition of apoptosis as illustrated by a higher BCLX-L/BAX ratio on
9 whole ovarian lysed tissues. In addition, C1P was associated with rescue of fertility [57].

10

11 Anti-Müllerian hormone (AMH)

12 AMH, a member of transforming growth factor beta family, is known for its role in inducing the
13 regression of Müllerian ducts in male sex differentiation [58]. Lower rate of developing follicles were
14 observed in *in vitro* cultures of human ovaries cultured with AMH, suggesting a role in PF dormancy
15 [59]. Co-administration of DOX, carboplatin or CY with recombinant human AMH (rhAMH) in
16 peripuberal 6- to 7-week-old mice was associated with higher rate of PF [60]. Additionally number of
17 eggs following gonadotropins injections and number of pups after mating from co-treated mice was
18 comparable to control [61]. Co-administration of CY and AMH were associated with a slight decrease
19 in pPS6K compared to CY-alone in 6-week-old Swiss mice. This suggests that AMH impact on PF
20 growth is mediated through mTOR pathway [61].

21

22 Granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF)

23 G-CSF (filgrastim) alone or with SCF was concomitantly administered with CY and busulfan in 6-week-
24 old mice. Higher number of PF was found in mice which received G-CSF alone or with SCF. After
25 cytotoxic treatment, microvessel density measured by immunohistochemical staining for PECAM-
26 1/CD31 increased when G-CSF alone or with SCF were administered. It was associated with higher
27 rate litters and pups [62].

28

29

30

1 Dexrazoxane

2 Dexrazoxane is known for prevention of cardiologic and extravasation injuries from anthracyclines
3 [63]. In mice, associated with DOX, dexrazoxane reduced double strand breaks in ovarian cells more
4 particularly granulosa cells [64,65]. TUNEL assay revealed an effect on secondary follicles but not PF.
5 PF pool was not reported but co-administration was associated with reduced infertility index [65].

6
7 Curcumin capsaicin

8 Curcumin and capsaicin, two dietary compound [66,67], were studied after CY injection in Wistar rats.
9 Oxidative stress markers in rats were comparable to controls and histological analyses revealed lower
10 rate of ovarian damage. But effects of these compound on PF pool and fertility were not reported [68].

11
12 Shilajit

13 Shilajit, a complex mixture of organic compounds which exudes from mountain rocks [69],
14 administered after 8.3 Gy total body irradiation in Wistar rats was associated with higher PF counts
15 [70].

16
17 Manganese dipyridoxyl diphosphate (mangafodipir)

18 Mangafodipir is used in magnetic resonance imaging and has some antioxidant activities [71]. CIS and
19 paclitaxel treatment with mangafodipir in 6-week-old mice was associated with higher count of PF with
20 a reduced expression of Ki67 illustrating the inhibition PF growth. Concomitantly, a reduction in
21 oxidative stress, analyzed by lipid peroxidation assays, was observed notably in granulosa cells and
22 follicles [72], suggesting that mangafodipir may prevent PF loss by preventing ROS-mediated
23 damages.

24
25 Resveratrol

26 Resveratrol is a polyphenolic phytoalexin found in grapes and raisins. It is thought to exert antioxidant
27 activities [73]. Resveratrol rescued viability and decreased levels of cellular ROS of rat granulosa cells
28 cultured with CY [74]. But cultures of ovarian sheep tissues revealed that resveratrol alone was
29 associated with lower PF count possibly mediated by PI3K pathway activation [75].

30

1 DISCUSSION AND PERSPECTIVES

2

3 Not all anticancer treatments are associated with POF. In this review, we highlight the ovarian reserve-
4 protecting effects of some such treatments, through their impact on PF activation and apoptosis
5 pathways. In mouse models, combinations of certain targeted therapies and classic cytotoxic
6 treatments has been shown to prevent exhaustion of the PF pool (Figure 4B).

7 The PI3K/Akt/mTOR pathway is the cornerstone of PF activation. mTOR inhibitors may
8 promote PF quiescence during cytotoxic treatments. The level of proof for this finding currently
9 extends to *ex vivo* models of cultured human ovaries, suggesting feasibility for use in humans
10 [14,18,19]. Nevertheless, adding an immunosuppressive drug to the treatment regimen may increase
11 the risk of infection in patients who are already immunocompromised. New PI3K inhibitors, such as
12 idelalisib, may also target PI3K pathways and could be evaluated *in vitro* [76].

13 KIT and ABL are involved in PF activation and apoptosis after chemotherapy, respectively
14 [9,12]. The impact of ABL and KIT inhibitors on PF pathways remains a matter of debate. Gonfloni *et al.*
15 demonstrated that imatinib prevents PF death from CY-induced apoptosis in a mouse model [9].
16 However, this blocking of apoptosis by imatinib in the context of double-strand breaks could potentially
17 results in the conservation of oocytes with chemotherapy-related acquired cytogenetic abnormalities.
18 But Kim *et al.* reported better tissue recovery in mice receiving grafts of co-treated ovaries than in
19 those receiving grafts treated with CIS alone [26]. Imatinib inhibits KIT and might therefore be useful
20 for blocking PF activation, and therefore limiting PF loss [32]. However, in a different model of CIS-
21 treated mice, Kerr *et al.* found that imatinib had no beneficial effects for ovarian reserve protection,
22 suggesting that the effects of imatinib may not be reproducible in different conditions [24]. Another
23 study showed that the dose and manufacturer of the CIS used for treatment affected the results
24 obtained [25]. Sunitinib was found to block PF activation in mice after superovulation, but its impact on
25 mice receiving chemotherapy is unknown [38]. Inhibition profiles differ between TKIs, so explorations
26 of other KIT inhibitors are warranted [77].

27 Other approaches have been evaluated, including the prevention of DOX transport into the
28 nucleus by proteasome inhibition, for example [46]. According to the hypothesis underlying this
29 approach, bortezomib might be expected to decrease the anti-tumoral efficacy of DOX. However,
30 adding bortezomib to DOX-containing polychemotherapy for diffuse large B-cell lymphoma did not

1 shorten progression-free or overall survival [78]. GSK3 inhibitors have been studied as ROS
2 modulators, probably exerting their effects by improving the antioxidant activities of Nrf2 after DOX
3 administration [23]. GSK3 is inactivated by pArk, suggesting that GSK3 inhibitors might affect the
4 PI3K/Akt/mTOR-mediated activation of PF growth after treatment with CY [47].

5 Surprisingly, two independent groups using different methods observed that some cytotoxic
6 agents protected the ovarian reserve in humans [50,51]. However, these results might also be
7 explained by uncontrolled confusion bias; synergistic effects of certain chemotherapy agents on the
8 ovarian reserve; possible false-positive results; publication bias. In studies based on the same
9 methodology, no PF pool preservation after ABVD was observed in our institution (unpublished
10 results).

11 Precautions must be taken when using targeted therapies. Current evidence concerning their
12 impact on the ovarian reserve mostly relates to *in vivo* murine or *ex vivo* human ovarian culture
13 models. Imatinib has been studied preferentially in young mice, whereas mTOR inhibitors have been
14 studied mostly in eight-week-old mice. Results for cultured human ovaries treated with imatinib have
15 suggested that the findings for the ABL/TAp63 pathway in mice are not relevant to humans [9,25,36].
16 Conversely, the effect of the mTOR inhibitor everolimus on the PI3K/Akt/mTOR pathway seems to be
17 reproducible in humans [14]. Murine models can be used to study the pharmacodynamics of the
18 molecules, but the protocols used for evaluations have been heterogeneous (Table 1). The targeted
19 therapy was administered at the same time as the cytotoxic agent in some studies, and before it in
20 others. Furthermore, mice of different ages were used for these experiments. Similarly, the effects of
21 targeted treatments were evaluated during only one cycle of cytotoxic treatment, at a particular time
22 point. The effect of supposedly protective treatments on the ovarian reserve after multiple cycles of
23 cytotoxic treatment therefore remains unknown. The dose of cytotoxic agent may also have a major
24 impact on the protective effect of the drug. In CIS-treated mice, high doses of CIS abolished the
25 effects of imatinib on apoptosis [24,25]. Similarly, chemotherapy protocols often combine multiple
26 agents with different effects on the cell cycle over a specific time sequence. The additive, synergic or
27 antagonist effects on the PF pool of the targeted therapy in association with cytotoxic agents require
28 evaluation.

29 Data for humans are therefore warranted, to find new targetable pathways and to evaluate the
30 safety and feasibility of these co-administration procedures. Given the potentially large number of

1 pathways involved in cytotoxicity-related PF exhaustion, multi-omics approaches associating
2 transcriptomic and proteomic studies might facilitate the identification of new targetable pathways
3 modified by chemotherapy. An analysis of tissues from patients included in prospective studies
4 cryopreserved for the purposes of fertility preservation, involving a single randomized targeted
5 treatment, could provide preclinical data for the evaluation of such treatments. The subsequent design
6 of prospective trials is likely to be a major challenge. The bioavailability of these molecules in ovarian
7 tissues is unknown. The administration sequence must be defined, as there is increasing evidence for
8 pharmacological interactions affecting the pharmacodynamics of anticancer treatments [79]. Potential
9 interactions will, therefore need to be assessed before administration with cytotoxic agents, to prevent
10 toxicity and decreases in efficacy.

11 Apart from anticancer treatments, other molecules like sphingolipids, AMH, G-CSF,
12 dexrazoxane, curcumin, capsaicin, shilajit, mangafodipir, resveratrol may target PF exhaustion
13 mechanisms by preventing stroma injury or by the inhibition of apoptosis, ROS generation or PI3K
14 pathway. Data regarding the POF preventive effect of these molecules are restricted to mice models
15 and little is known on their respective mechanisms of action. Some of these approach may be limited
16 by their feasibility in human. In example: (i) G-CSF dose in mice was 10 times the dose used in febrile
17 neutropenia prevention [62] (ii) the equivalent dose of curcumin and shilajit for a 70 kg female patient
18 would be 7 kg (100 mg/kg used in rats) [68,70].

19 Fertility preservation strategies that rely on embryos, oocyte cryopreservation are not
20 appropriate in emergency conditions or in patients with hormone-sensitive cancers. In addition,
21 surgical procedures for ovarian tissue cryopreservation may not be suitable in the context of
22 hematological disorders [1,4,80]. Hormone suppression with gonadotropin-releasing hormone agonist
23 (GnRHa) is indicated for premenopausal breast cancer patients [80,81] but its effect on other cancer
24 subtypes remains controversial [82,83]. If the co-administration of a targeted drug with cytotoxic
25 treatment proves to be feasible with no increase in toxicity it could be used in fertility preservation
26 regardless the cancer subtype. Co-administration protocols might slow PF exhaustion, and could be
27 used alone or in association with other strategies, such as ovarian tissue transplantation, which is
28 more effective at high follicle density [84]. By stopping follicle activation, the co-treatment strategy
29 might also increase the follicular content of the ovary and improve ovarian tissue quality, thereby
30 promoting the recovery of ovarian tissue function after transplantation. Co-treatment strategies may

1 also be useful in emergency situations in which cryopreservation is impossible. Another strategy could
2 consider the use of targeted therapies preventing PF activation may be used after cancer treatment, to
3 delay POF further.

4

5 **CONCLUSIONS**

6

7 Cytotoxic agents, including alkylating agents in particular, are the most damaging anticancer
8 treatments, but other drugs may not reduce the PF pool. The studies performed to date have
9 highlighted the prevention of PF activation by the co-administration of mTOR inhibitors with cytotoxic
10 treatment. These results should stimulate reflections about alternative fertility preservation strategies.
11 Nevertheless, the available evidence was mostly obtained from mouse models, and there is, therefore,
12 still a need for more clinical data based on studies of human tissues before evaluations of these
13 protective studies in humans can be envisaged.

14

15

16 **Acknowledgments:** Not applicable

17 **Disclosure:** The authors have no conflicts of interest to declare.

18

19

20

21

22

23

24

25

26

27

28

29

30

31

1 REFERENCES

- 2 1. Salama M, Anazodo A, Woodruff TK. Preserving fertility in female patients with hematological
3 malignancies: a multidisciplinary oncofertility approach. *Ann Oncol*. 2019;30(11):1760-1775.
- 4 2. Podfigurna-Stopa A, Czyzyk A, Grymowicz M, et al. Premature ovarian insufficiency: the context
5 of long-term effects. *J Endocrinol Invest*. 2016;39(9):983-990.
- 6 3. Chemaitilly W, Li Z, Krasin MJ, et al. Premature ovarian insufficiency in childhood cancer
7 survivors: A report from the St. Jude lifetime cohort. *J Clin Endocrinol Metab*. 2017;102(7):2242-
8 2250.
- 9 4. Kim SY, Kim SK, Lee JR, et al. Toward precision medicine for preserving fertility in cancer
10 patients: existing and emerging fertility preservation options for women. *J Gynecol Oncol*.
11 2016;27(2):e22.
- 12 5. Poirot C, Abirached F, Prades M, et al. Induction of puberty by autograft of cryopreserved ovarian
13 tissue. *Lancet*. 2012;379(9815):588.
- 14 6. Poirot C, Fortin A, Dhédin N, et al. Post-transplant outcome of ovarian tissue cryopreserved after
15 chemotherapy in hematological malignancies. *Haematologica*. 2019;104(8):e360-e363
- 16 7. Adhikari D, Liu K. Molecular mechanisms underlying the activation of mammalian primordial
17 follicles. *Endocr Rev*. 2009;30(5):438-464.
- 18 8. Reddy P, Liu L, Adhikari D, et al. Oocyte-specific deletion of Pten causes premature activation of
19 the primordial follicle pool. *Science*. 2008;319(5863):611-613.
- 20 9. Gonfloni S, Tella LD, Caldarola S, et al. Inhibition of the c-Abl-TAp63 pathway protects mouse
21 oocytes from chemotherapy-induced death. *Nat Med*. 2009;15(10):1179-1185.
- 22 10. Hansen KR, Knowlton NS, Thyer AC, et al.. A new model of reproductive aging: the decline in
23 ovarian non-growing follicle number from birth to menopause. *Hum Reprod*. 2008;23(3):699-708.
- 24 11. Reddy P, Zheng W, Liu K. Mechanisms maintaining the dormancy and survival of mammalian
25 primordial follicles. *Trends Endocrinol Metab*. 2010;21(2):96-103.
- 26 12. Nilsson EE, Detzel C, Skinner MK. Platelet-derived growth factor modulates the primordial to
27 primary follicle transition. *Reproduction*. 2006;131(6):1007-1015.
- 28 13. Sutherland JM, Frost ER, Ford EA, et al. Janus kinase JAK1 maintains the ovarian reserve of
29 primordial follicles in the mouse ovary. *Mol Hum Reprod*. 2018;24(11):533-542.

- 1 14. Grosbois J, Demeestere I. Dynamics of PI3K and Hippo signaling pathways during *in vitro* human
2 follicle activation. Hum Reprod. 2018;33(9):1705-1714.
- 3 15. Morgan S, Anderson RA, Gourley C, et al. How do chemotherapeutic agents damage the ovary?
4 Hum Reprod Update. 2012;18(5):525-535.
- 5 16. Oktem O, Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle
6 reserve and stromal function. Cancer. 2007;110(10):2222-2229.
- 7 17. Oktem O, Oktay K. A novel ovarian xenografting model to characterize the impact of
8 chemotherapy agents on human primordial follicle reserve. Cancer Res. 2007;67(21):10159-
9 10162.
- 10 18. Zhou L, Xie Y, Li S, et al. Rapamycin prevents cyclophosphamide-induced over-activation of
11 primordial follicle pool through PI3K/Akt/mTOR signaling pathway *in vivo*. J Ovarian Res.
12 2017;10(1):56.
- 13 19. Goldman KN, Chenette D, Arju R, et al. mTORC1/2 inhibition preserves ovarian function and
14 fertility during genotoxic chemotherapy. Proc Natl Acad Sci USA. 2017;114(12):3186-3191.
- 15 20. Kalich-Philosoph L, Roness H, Carmely A, et al. Cyclophosphamide triggers follicle activation and
16 "burnout"; AS101 prevents follicle loss and preserves fertility. Sci Transl Med.
17 2013;5(185):185ra62.
- 18 21. Soleimani R, Heytens E, Darzynkiewicz Z, et al. Mechanisms of chemotherapy-induced human
19 ovarian aging: double strand DNA breaks and microvascular compromise. Aging (Albany NY).
20 2011;3(8):782-793.
- 21 22. Morgan S, Lopes F, Gourley C, et al. Cisplatin and doxorubicin induce distinct mechanisms of
22 ovarian follicle Loss; imatinib provides selective protection only against cisplatin. PLoS One.
23 2013;8(7):e70117.
- 24 23. Niringiyumukiza JD, Cai H, Chen L, et al. Protective properties of glycogen synthase kinase-3
25 inhibition against doxorubicin-induced oxidative damage to mouse ovarian reserve. Biomed
26 Pharmacother. 2019;116:108963.
- 27 24. Kerr JB, Hutt KJ, Cook M, et al. Cisplatin-induced primordial follicle oocyte killing and loss of
28 fertility are not prevented by imatinib. Nat Med. 2012;18(8):1170-1172.
- 29 25. Maiani E, Di Bartolomeo C, Klinger FG, et al. Reply to: cisplatin-induced primordial follicle oocyte
30 killing and loss of fertility are not prevented by imatinib. Nat Med. 2012;18(8):1172-1174.

- 1 26. Kim SY, Cordeiro MH, Serna VA, et al. Rescue of platinum-damaged oocytes from programmed
2 cell death through inactivation of the p53 family signaling network. *Cell Death Differ.*
3 2013;20(8):987-997
- 4 27. Fabbri R, Macciocca M, Vicenti R, et al. Doxorubicin and cisplatin induce apoptosis in ovarian
5 stromal cells obtained from cryopreserved human ovarian tissue. *Futur Oncol.* 2016;12(14):1699-
6 1711.
- 7 28. Bar-Joseph H, Ben-Aharon I, Tzabari M, et al. *In vivo* bioimaging as a novel strategy to detect
8 doxorubicin-induced damage to gonadal blood vessels. *PLoS One.* 2011;6(9):e23492.
- 9 29. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine
10 kinase on the growth of Bcr-Abl positive cells. *Nat Med.* 1996;2(5):561-566.
- 11 30. Bantscheff M, Eberhard D, Abraham Y, et al. Quantitative chemical proteomics reveals
12 mechanisms of action of clinical ABL kinase inhibitors. *Nat Biotechnol.* 2007;25(9):1035-1044.
- 13 31. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits *in vitro*
14 signal transduction mediated by c-kit and platelet-derived growth factor receptors. *J Pharmacol*
15 *Exp Ther.* 2000;295(1):139-145.
- 16 32. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in
17 advanced gastrointestinal stromal tumors. *N Engl J Med.* 2002;347(7):472-480.
- 18 33. Jaeckle KA, Anderson SK, Twohy EL, et al. Phase I-II trial of imatinib mesylate (Gleevec; STI571)
19 in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North Central Cancer
20 Treatment Group Study N0272 (ALLIANCE/NCCTG). *J Neurooncol.* 2019;143(3):573-581.
- 21 34. Schultheis B, Nijmeijer BA, Yin H, et al. Imatinib mesylate at therapeutic doses has no impact on
22 folliculogenesis or spermatogenesis in a leukaemic mouse model. *Leuk Res.* 2012;36(3):271-274.
- 23 35. Asadi-azarbaijani B, Santos RR, Jahnukainen K, et al. Developmental effects of imatinib mesylate
24 on follicle assembly and early activation of primordial follicle pool in postnatal rat ovary. *Reprod*
25 *Biol.* 2017;17(1):25-33.
- 26 36. Bildik G, Acilan C, Sahin GN, et al. C-Abl is not activated in DNA damage-induced and Tap63-
27 mediated oocyte apoptosis in human ovary. *Cell Death Dis.* 2018;9(10):943.
- 28 37. Nassif E, Thibault C, Vano Y, et al. Sunitinib in kidney cancer: 10 years of experience and
29 development. *Expert Rev Anticancer Ther.* 2017;17(2):129-142.

- 1 38. Bernard V, Bouilly J, Kramer P, et al. The tyrosine kinase inhibitor sunitinib affects ovulation but
2 not ovarian reserve in mouse: a preclinical study. *PLoS One*. 2016;11(4):e0152872.
- 3 39. Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: A review of the
4 evidence. *Kidney Int*. 2001;59(1):3-16.
- 5 40. O'Shaughnessy J, Thaddeus Beck J, Royce M. Everolimus-based combination therapies for HR⁺,
6 HER2⁻ metastatic breast cancer. *Cancer Treat Rev*. 2018;69:204-214.
- 7 41. Xhaard A, Launay M, Sicre de Fontbrune F, et al. A monocentric study of steroid-refractory acute
8 graft-versus-host disease treatment with tacrolimus and mTOR inhibitor. *Bone Marrow*
9 *Transplant*. 2020;55(1):86-92.
- 10 42. Adhikari D, Risal S, Liu K, et al. Pharmacological inhibition of mTORC1 prevents over-activation
11 of the primordial follicle pool in response to elevated PI3K signaling. *PLoS One*.
12 2013;8(1):e53810.
- 13 43. Zhang XM, Li L, Xu JJ, et al. Rapamycin preserves the follicle pool reserve and prolongs the
14 ovarian lifespan of female rats via modulating mTOR activation and sirtuin expression. *Gene*.
15 2013;523(1):82-87.
- 16 44. Scott K, Hayden PJ, Will A, et al. Bortezomib for the treatment of multiple myeloma. *Cochrane*
17 *Database Syst Rev*. 2016;4:CD010816.
- 18 45. Kiyomiya K, Matsuo S, Kurebe M. Mechanism of Specific Nuclear Transport of Adriamycin: The
19 Mode of Nuclear Translocation of Adriamycin-Proteasome Complex. *Cancer Res*.
20 2001;61(6):2467-2471.
- 21 46. Roti Roti EC, Ringelstetter AK, Kropp J, et al. Bortezomib prevents acute doxorubicin ovarian
22 insult and follicle demise, improving the fertility window and pup birth weight in mice. *PLoS One*.
23 2014;9(9):e108174.
- 24 47. Hermida MA, Dinesh Kumar J, Leslie NR. GSK3 and its interactions with the PI3K/AKT/mTOR
25 signalling network. *Adv Biol Regul*. 2017;65:5-15.
- 26 48. Rojo AI, Sagarra MR, Cuadrado A. GSK-3beta down-regulates the transcription factor Nrf2 after
27 oxidant damage: Relevance to exposure of neuronal cells to oxidative stress. *J Neurochem*.
28 2008;105(1):192-202.

- 1 49. Hayun M, Naor Y, Weil M, et al. The immunomodulator AS101 induces growth arrest and
2 apoptosis in multiple myeloma: association with the Akt/survivin pathway. *Biochem Pharmacol.*
3 2006;72(11):1423-1431.
- 4 50. McLaughlin M, Kelsey TW, Wallace WH, et al. Non-growing follicle density is increased following
5 Adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy in the adult human
6 ovary. *Hum Reprod.* 2017;32(1):165-174.
- 7 51. Green DM, Kawashima T, Stovall M, et al. Fertility of female survivors of childhood cancer: a
8 report from the childhood cancer survivor study. *J Clin Oncol.* 2009;27(16):2677-2685.
- 9 52. Winship AL, Carpenter M, Griffiths M, et al. Vincristine chemotherapy induces atresia of growing
10 ovarian follicles in mice. *Toxicol Sci.* 2019;169(1):43-53.
- 11 53. The Human Metabolome Database, Sphingosine-1-phosphate. Available at
12 <https://hmdb.ca/metabolites/HMDB0000277>. Accessed November 26, 2020.
- 13 54. The Human Metabolome Database, Ceramide-1-phosphate. Available at
14 <https://hmdb.ca/metabolites/HMDB0010699>. Accessed November 26, 2020.
- 15 55. Fang L, Turan V, Lierman S, et al. Sphingosine-1-phosphate prevents chemotherapy-induced
16 human primordial follicle death. *Hum Reprod.* 2014;29(1):107-113.
- 17 56. Tan SJ, Lee LJ, Tzeng CR, et al. Targeted anti-apoptosis activity for ovarian protection against
18 chemotherapy-induced ovarian gonadotoxicity. *Reprod Biomed Online.* 2014;29(5):612-620.
- 19 57. Pascuali N, Scotti L, Di Pietro M, et al. Ceramide-1-phosphate has protective properties against
20 cyclophosphamide-induced ovarian damage in a mice model of premature ovarian failure. *Hum*
21 *Reprod.* 2018;33(5):844-859.
- 22 58. Moolhuijsen LME, Visser JA. Anti-Müllerian Hormone and Ovarian Reserve: Update on
23 Assessing Ovarian Function. *J Clin Endocrinol Metab.* 2020;105(11):3361-3373.
- 24 59. Carlsson IB, Scott JE, Vissier JA et al. Anti-Müllerian hormone inhibits initiation of growth of
25 human primordial ovarian follicles in vitro. *Hum Reprod.* 2006;21(9):2223-2227.
- 26 60. Kano M, Sosulski AE, Zhang L, et al. AMH/MIS as a contraceptive that protects the ovarian
27 reserve during chemotherapy. *Proc Natl Acad Sci U S A.* 2017;114(9):E1688-E1697.
- 28 61. Sonigo C, Beau I, Grynberg M, et al. AMH prevents primordial ovarian follicle loss and fertility
29 alteration in cyclophosphamide-treated mice. *FASEB J.* 2019;33(1):1278-1287.

- 1 62. Skaznik-Wikiel ME, McGuire MM, Sukhwani M, et al. Granulocyte colony-stimulating factor with
2 or without stem cell factor extends time to premature ovarian insufficiency in female mice treated
3 with alkylating chemotherapy. *Fertil Steril*. 2013;99(7):2045-2054.e3.
- 4 63. Doroshov JH. Dexrazoxane for the prevention of cardiac toxicity and treatment of extravasation
5 injury from the anthracycline antibiotics. *Curr Pharm Biotechnol*. 2012;13(10):1949-1956.
- 6 64. Roti Roti EC, Salih SM. Dexrazoxane ameliorates doxorubicin-induced injury in mouse ovarian
7 cells. *Biol Reprod*. 2012;86(3):96.
- 8 65. Kropp J, Roti Roti EC, Ringelstetter A et al. Dexrazoxane Diminishes Doxorubicin-Induced Acute
9 Ovarian Damage and Preserves Ovarian Function and Fecundity in Mice. *PLoS One*.
10 2015;10(11):e0142588.
- 11 66. The Human Metabolome Database, Curcumin. Available at
12 <https://hmdb.ca/metabolites/HMDB0002269>. Accessed November 26, 2020.
- 13 67. The Human Metabolome Database, Capsaicin. Available at
14 <https://hmdb.ca/metabolites/HMDB0002227>. Accessed November 26, 2020.
- 15 68. Melekoglu R, Ciftci O, Eraslan S, et al. Beneficial effects of curcumin and capsaicin on
16 cyclophosphamide-induced premature ovarian failure in a rat model. *J Ovarian Res*.
17 2018;11(1):33.
- 18 69. Agarwal SP, Khanna R, Karmarkar R, et al. Shilajit: a review. *Phytother Res*. 2007;21(5):401-405.
- 19 70. Kececi M, Akpolat M, Gulle K, et al. Evaluation of preventive effect of shilajit on radiation-induced
20 apoptosis on ovaries. *Arch Gynecol Obstet*. 2016;293(6):1255-1262.
- 21 71. Spath NB, Thompson G, Baker AH, et al. Manganese-enhanced MRI of the myocardium. *Heart*.
22 2019;105(22):1695-1700.
- 23 72. Qin Y, Iwase A, Murase T, et al. Protective effects of mangafodipir against chemotherapy-induced
24 ovarian damage in mice. 2018;16(1):106.
- 25 73. The Human Metabolome Database, Resveratrol. Available at
26 <https://hmdb.ca/metabolites/HMDB0003747>. Accessed November 26, 2020
- 27 74. Nie Z, Zhang L, Chen W, et al. The protective effects of pretreatment with resveratrol in
28 cyclophosphamide-induced rat ovarian granulosa cell injury: In vitro study. *Reprod Toxicol*.
29 2020;95:66-74.

- 1 75. Bezerra MA, Gouveia BB, Barberino RS, et al. Resveratrol promotes in vitro activation of ovine
2 primordial follicles by reducing DNA damage and enhancing granulosa cell proliferation via
3 phosphatidylinositol 3-kinase pathway. *Reprod Domest Anim.* 2018;53(6):1298-1305.
- 4 76. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic
5 lymphocytic leukemia. *N Engl J Med.* 2014;370(11):997-1007.
- 6 77. Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity.
7 *Nat Biotechnol.* 2008;26(1):127-132.
- 8 78. Davies A, Cummin TE, Barrans S, et al. Gene-expression profiling of bortezomib added to
9 standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label,
10 randomised, phase 3 trial. *Lancet Oncol.* 2019;20(5):649-662.
- 11 79. Min JS, Bae SK. Prediction of drug–drug interaction potential using physiologically based
12 pharmacokinetic modeling. *Arch Pharm Res.* 2017;40(12):1356-1379.
- 13 80. Lambertini M, Peccatori FA, Demeestere I, et al. Fertility preservation and post-treatment
14 pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines. *Ann Oncol.*
15 2020 (in press).
- 16 81. Lambertini M, Moore HCF, Leonard RCF, et al. Gonadotropin-Releasing Hormone Agonists
17 During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal
18 Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-
19 Level Data. *J Clin Oncol.* 2018;36(19):1981-1990.
- 20 82. Demeestere I, Brice P, Peccatori FA, et al. Gonadotropin-releasing hormone agonist for the
21 prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up
22 of a prospective randomized trial. *J Clin Oncol.* 2013;31(7):903-909.
- 23 83. Turan V, Bedoschi G, Rodriguez-Wallberg K, et al. Utility of Gonadotropin-Releasing Hormone
24 Agonists for Fertility Preservation: Lack of Biologic Basis and the Need to Prioritize Proven
25 Methods. *J Clin Oncol.* 2019;37(1):84-86.
- 26 84. Poirot C, Fortin A, Lacorte JM, et al. Impact of cancer chemotherapy before ovarian cortex
27 cryopreservation on ovarian tissue transplantation. *Hum. Reprod.* 2019;34(6):1083-1094.
- 28
- 29
- 30

1 **FIGURE LEGENDS**

2

3 **Figure 1. Indexed references in PubMed identified with the keywords ‘cancer targeted**
4 **therapies’ from 1980 to 2018.**

5

6 **Figure 2. Change in primordial follicle count over time, and influence of cytotoxic agents on**
7 **ovarian decay.** In black: the pool of primordial follicles (ovarian reserve) is fixed at birth. In healthy
8 women, the number of primordial follicles decreases with age, resulting in menopause. In red:
9 cytotoxic treatment may lead to apoptosis or trigger follicle activation, leading to ovarian reserve
10 exhaustion and premature ovarian failure (POF).

11

12 **Figure 3. Main pathways involved in follicle activation leading to the initiation of follicular**
13 **growth.** The PI3K/Akt/mTOR pathway is triggered by the binding of KIT-ligand (KIT-L) to its receptor
14 (KIT). Environmental factors also regulate follicular growth: cell-to-cell contact (Hippo signaling),
15 stromal signals (BMP-4 and KGF) or cytokine-like platelet-derived growth factor (PDGF), basic
16 fibroblast growth factor (bFGF) and leukemia inhibitory factor (LIF).

17

18 **Figure 4. Impact of cytotoxic agents on pathways involved in primordial follicle pool**
19 **exhaustion.** (A) Main mechanisms involved in primordial follicle pool exhaustion during
20 chemotherapy. (B) Hypothetical targetable pathways for inhibiting apoptosis or follicle activation in
21 patients treated with cytotoxic agents.

Table 1. Evidence for protective effects of anticancer drugs on the ovarian reserve.

Class	Molecule	Reference	Model		Administration	Dose/day	Co-administered cytotoxic agent	Administration sequence	Effects on ovarian reserve relative to control	Effect on <i>in vivo</i> fertility
Tyrosine kinase inhibitor	Imatinib	Kim et al. [26]	<i>In vitro</i> culture then grafted into mice	CD57BL/6 PND 5 (ovaries) and 3-week-old mice (grafted)	Medium	5 µM	CIS SIGMA (4 µM)	In culture: cisplatin day 1 imatinib days 2 to 4 then grafted into syngeneic ovariectomized mice	Day+14 after graft: better tissue recovery and higher PF count	NR
		Schultheis et al. [34]	<i>In vivo</i> , mice	C3H/HeJ 5-week-old mice injected with BCR-ABL cell lines	Oral (water)	3 mg (150 mg/kg) 50 days	No	N/A	After 2 months of continuous treatment: PF pool similar to control Ovary architecture disorganized	NR
		Gonfloni et al. [9]	<i>In vivo</i> , mice	CD1 PND 5 and 7	IP	7.5 mg/kg once	CIS SIGMA (5 mg/kg)	Simultaneous	PND 10: higher counts of pooled primordial and primary follicles	Larger number of pups in litters from co-treated mice
		Kerr et al. [24]	<i>In vivo</i> , mice	CD1 & C57BL/6 PND 5 and 7	IP	7.5 mg/kg once	CIS HG (5 mg/kg)	Simultaneous	PND 10 and PND 49: similar depletion of PF	No difference between CIS- and co-treated mice
			<i>In vivo</i> , mice	C57BL/6 PND 5 and 7	IP	7.5 mg/kg once	CIS HG (5 mg/kg)	Imatinib 2 hours before CIS	PND 10 and PND 49: similar depletion of PF	NR
		Asadi-Azarbaijani et al. [35]	<i>In vivo</i> , rats	Sprague Dawley PND 2	Intracavitary (stomach) injections	150 mg/kg 3 days	No	N/A	PND 5: increase in number of oogonia, induce in the quiescence of granulosa cells	NR
		Morgan et al. [22]	<i>Ex vivo</i> ovarian cultures, mice	C57BL/6J newborn	Medium	N/A	DOX CIS SIGMA	Imatinib days 1 to 3 cytotoxic agent day 2	After 6 days of culture: smaller numbers of unhealthy follicles in CIS group	N/A
		Bildik et al. [36]	<i>Ex vivo</i> cultures, human	Female patients with benign ovarian cysts (mean age 27 years)	Medium	10 µM	CIS Eli Lilly and Company 20 µM	Imatinib 2 hours before CIS	At 24h, similar depletion of PFs and bizarre-shaped primordial follicles	N/A
	Human ovaries xenografted, mice		Nude mice 8 weeks old	IP	7.5 mg/kg	CIS Eli Lilly and Company 5 mg/kg	Imatinib 2 hours before CIS	At 24h, similar depletion of PFs and bizarre-shaped primordial follicles	NR	
	Sunitinib	Bernard et al. [38]	<i>In vivo</i> , mice	NR 3 to 6 weeks old	oral	50 mg/kg 35 days	no	N/A	less response to superovulation test	No difference relative to untreated mice

mTOR inhibitors	Rapamycin	Adhikari et al. [42]	<i>In vivo</i> , mice	B57BL/6J <i>OoPten</i> ^{-/-} PND 4	IP	5 mg/kg 19 days	No	N/A	PND 23: increase in PF pool	NR
		Zhang et al. [43]	<i>In vivo</i> , rats	Sprague Dawley 8 weeks old	IP	5 mg/kg 10 weeks	No	N/A	After 10 weeks: increase in PF pool	NR
		Zhou et al. [18]	<i>In vivo</i> , mice	BALB/c 8 weeks old	NR	5 mg/kg once	CY (75-100-150 mg/kg)	Rapamycin 1 week before and after CY	7 days after last CY injection: increase in PF pool	NR
	Sapanisertib	Goldman et al. [19]	<i>In vivo</i> , mice	C57BL/6 8 weeks old	NR	0.3 mg/kg	CY (75 mg/kg)	Sapanisertib daily days 1-5 of weeks 1-3, and days 1-4 of week 4; CY on day 3 of weeks 1-3	1 week after last CY injection: increase in PF pool	More pups and no infertility in co-treated mice
		Everolimus	Goldman et al. [19]	<i>In vivo</i> , mice	C57BL/6 8 weeks old	NR	2.5 mg/kg	CY (75 mg/kg)	Everolimus daily days 1-5 of weeks 1-3, and days 1-4 of week 4; CY on day 3 of weeks 1-3	1 week after last CY injection: increased PF pool
	Grosbois et al. [14]		<i>Ex vivo</i> cultures, human	19-29 years old female	medium	N/A	No	N/A	Higher PF count	N/A
Proteasome inhibitor	Bortezomib	Roti Roti et al. [46]	<i>In vivo</i> , mice	CD1 4 weeks old	IP	0.143 mg/kg once	DOX (20 mg/kg)	Bortezomib 1 hour before DOX	Not assessed	Longer fertility and more pups per litter
GSK3 inhibitor	SB216763	Niringiyum ukiza et al. [23]	<i>In vivo</i> , mice	ICR 7-8 weeks old	IP	5-10 mg/kg	DOX (10 mg/kg)	10 mg/kg before single-dose DOX and 5 mg/kg 3 times per week for 2 weeks	3 weeks after DOX injection: increase in PF pool	N/A
Cytotoxic agents	DOX	Green et al. [51]	Human, retrospective study	Female < 21 years old	N/A	N/A	N/A	N/A	N/A	RR of pregnancy: 1.22 (95%CI: 1.04-1.45)
	ABVD	McLaughlin et al. [50]	Human, retrospective study	Female patients	N/A	N/A	N/A	N/A	Higher PF count	NR
	Vincristine	Winship et al. [52]	<i>In vivo</i> , mice	C57BL/6 8 weeks old 6 months old	IP	1 mg/kg	N/A	Days 1, 4 and 8	No effect on PF pool	NR
Other	AS101	Kalich-Philosoph et al. [20]	<i>In vivo</i> , mice	BALB/c 8 weeks old	IP	10 µg	CY (75-100-150 mg/kg/week, 75 mg x4 mg/kg/week)	1 week before and after chemo	1 week after CY injection: increase in PF pool	More pups and larger litter size

ABVD: Adriamycin, bleomycin, vinblastine, dacarbazine; CY: cyclophosphamide; CIS: cisplatin; DOX: doxorubicin; HG: hospital-grade; PND: postnatal day IP: intraperitoneal; NR: not reported; PF: primordial follicles; RR: risk ratio




Figure 1




Figure 2




Figure 3



A**B**

Figure 4